Abstract | OBJECTIVES: The aim of this study was to evaluate the efficacy of drug-eluting balloons (DEB) with drug-eluting stents (DES) in patients with in- stent restenosis (ISR). BACKGROUND: METHODS: Electronic databases were searched for randomized controlled trials and observational cohort studies which reported the clinical outcomes of using DEB comparing with DES implantation in patients with ISR. Clinical endpoints such as major adverse cardiovascular events ( MACE), death, and myocardial infarction were assessed. RESULTS: Five randomized controlled trials and five observational cohort studies with 962 patients in the DEB group and 908 patients in the DES group met inclusion criteria. There was no significant difference between DEB and DES in major clinical outcomes, such as MACE (OR 1.01; 95% CI: 0.64-1.58; p=0.97; I2=0%), all-cause death (OR 1.04; 95% CI: 0.54-1.98; p=0.91; I2=0%), cardiovascular death (OR 1.44; 95% CI: 0.57-3.65; p=0.44; I2=0%), stent thrombosis (OR 0.61; 95% CI: 0.16-2.33; p=0.47; I2=0%), and myocardial infarction (OR 1.02; 95% CI: 0.53-1.94; p=0.96; I2=0%). DEB was associated with a significant increase in target lesion revascularization (OR 1.54; 95% CI: 1.10-2.15; p=0.01; I2=57%). CONCLUSION: Treatment of ISR using DEB led to comparable clinical outcomes with DES implantation.
|
Authors | Yanwei Wang, Xinmin Lou, Xiaomin Xu, Jianhua Zhu, Yunpeng Shang |
Journal | Journal of cardiology
(J Cardiol)
Vol. 70
Issue 5
Pg. 446-453
(Nov 2017)
ISSN: 1876-4738 [Electronic] Netherlands |
PMID | 28259383
(Publication Type: Journal Article, Meta-Analysis)
|
Copyright | Copyright © 2017 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved. |
Topics |
- Coronary Restenosis
(therapy)
- Drug Delivery Systems
(adverse effects)
- Drug-Eluting Stents
(adverse effects)
- Humans
- Observational Studies as Topic
- Percutaneous Coronary Intervention
- Randomized Controlled Trials as Topic
- Treatment Outcome
|